Official ESCRS | European Society of Cataract & Refractive Surgeons



Search Title by author or title

Use of plasma in the palpebral margin in patients with Meibomian gland dysfunction

Poster Details

First Author: C.Okazaki BRAZIL

Co Author(s):    R. Hazarbassanov   J. Gomes                 

Abstract Details


Evaluate the clinical efficacy of treatment of patients with meibomian gland dysfunction with a plasma jett device evaluating clinical and symptomatic evolution.


UNIFESP - Federal University of São Paulo.


The plasma will be applied above and below the orifice line of meibomius glands 3x, with a 14.4mm / 24.4mm tip with intensity 5-6 (0.9W) in the device, using surgical loupes with an increase of 4.5x. After application will be performed expression of the meibomian glands and the patient will be medicated for 10 days with antibiotic ointment with 2x daily steroid. Returns will occur in 1 day, 14 days and 3 months. Before the procedure and in all the returns we evaluated the meibomiography, schirmmer test, osmolarity and Ocular Surface Disease Index (OSDI) questionnaire.


Fifteen refractory patients were evaluated for clinical treatment of blepharitis without contraindications to plasma use and were compatible with inclusion criteria. There was improvement in physical examination, expression of meibomius glands as well as meibomiography. significant improvement in the OSDI questionnaire, the research is in progress we are awaiting feedback from patients already treated.


Jett plasma treatment is a promising, low-cost, low-invasive alternative for refractory meibomian gland dysfunction patients with other less invasive treatments.

Financial Disclosure:


Back to Poster listing